Patient Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Patient Capital Management's BIIB Position: Q2 2026 in Review
Patient Capital Management reduced its Biogen (BIIB) stake by 25% in Q2 2026, selling an estimated $18.4M and leaving 283,697 shares worth $61.3M. The position accounts for 2.01% of the portfolio, ranked #22.
Patient Capital Management first reported a position in BIIB in Q1 2024 and has held it in 10 quarters since. The position peaked at $101M in Q4 2025. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Patient Capital Management held 283,697 shares of Biogen worth $61.3M as of Q2 2026.
- Patient Capital Management sold 96,044 Biogen shares in Q2 2026, an estimated $18.4M.
- Biogen made up 2.01% of Patient Capital Management's portfolio in Q2 2026, its #22 holding.
- Patient Capital Management first reported a position in Biogen in Q1 2024 and has held it in 10 quarters since.
- Patient Capital Management's Biogen position peaked at $101M in Q4 2025.
- 1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Patient Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.